PSORIATIC arthritis treatment strategies showed comparable retention and safety after tumor necrosis factor inhibitor failure.
Psoriatic Arthritis Treatment After TNFi Failure
Treatment selection after tumor necrosis factor inhibitor failure in psoriatic arthritis remains a common clinical challenge, with limited evidence to guide whether clinicians should cycle to another TNFi or swap to a biologic disease modifying antirheumatic drug with a different mechanism of action.
A systematic review and meta-analysis found no significant differences between cycling and swapping strategies across key clinical outcomes, including lack of response, treatment retention, and adverse events. The findings suggest that psoriatic arthritis treatment after TNFi failure may be shaped more by clinical characteristics and patient preference than by a clear advantage for either approach.
Cycling And Swapping Show Comparable Outcomes
The analysis included five observational studies involving 2,300 patients with psoriatic arthritis. Most patients, 1,517, received a cycling strategy, while 783 received a swapping strategy. Disease duration before the second biologic disease modifying antirheumatic drug ranged from 3.7 to 12 years, reflecting a population with established disease and prior biologic exposure.
Lack of response, including primary nonresponse and secondary loss of response according to individual study definitions, was the main reason for discontinuing the first TNFi before treatment change. Across pooled analyses, cycling did not differ significantly from swapping for lack of response, with a risk ratio of 0.99 and a 95% confidence interval of 0.70 to 1.41.
Treatment retention also appeared similar. Twelve month retention showed a risk ratio of 0.91, with a 95% confidence interval of 0.75 to 1.10, while 24 month retention showed a risk ratio of 0.96, with a 95% confidence interval of 0.53 to 1.75. Adverse events were also comparable, with a risk ratio of 0.94 and a 95% confidence interval of 0.38 to 2.34.
Clinical Preference May Guide Psoriatic Arthritis Treatment
The absence of clear differences across effectiveness, retention, and safety outcomes supports a more individualized approach to psoriatic arthritis treatment after TNFi failure. For physicians managing patients with moderate to severe disease, the decision to cycle or swap may reasonably depend on prior response pattern, comorbidities, disease phenotype, patient priorities, and access considerations.
However, the evidence base remains limited to observational data, with substantial heterogeneity across outcomes. Further comparative research could help define which patients are most likely to benefit from cycling within TNFi therapy versus moving to biologic therapies with different mechanisms.
Reference
Tomo ATJ et al. Cycling versus swapping strategies for treatment of psoriatic arthritis after primary tumor necrosis factor inhibitors failure: a systematic review and meta-analysis. Rheumatology (Oxford). 2026;doi: 10.1093/rheumatology/keag281.
Featured Image: Yura Yarema on Adobe Stock.
